Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG0PEBp MYnJR|UxRTF|OT6yNQKBkcLz4pEJOU46PSEQvF2= M4H0OFI2QTZyMkiy
KellyCis83 NIW4NnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nk[FQ5KGh? M1PXb2lEPTB;MkWxMlAx6oDLwsJihKkyPS55NTFOwG0> MmHHNlU6PjB{OEK=
SK-N-AS Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXhOFghcA>? MWDJR|UxRTJ{Nz63NQKBkcLz4pEJNlIvOTVizszN MYKyOVk3ODJ6Mh?=
SK-N-ASCis24 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe0PEBp NEXqV4JKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>? M2LGR|I2QTZyMkiy
CHP-212 NUDQc2ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP3OFghcA>? M4HQXGlEPTB;Nz65O-KBkcLz4pEJNE43QSEQvF2= NFfESm8zPTl4MEK4Ni=>
CHP-212Cis100 NV:xSVF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi0PEBp NHTNVVVKSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN Mn71NlU6PjB{OEK=
U87  MlrMSpVv[3Srb36gRZN{[Xl? M1S0W|ExOCEQvF2= NUj3TnFTOjRvN{KgbC=> NFm5bWRqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= NIfUfJkzPThyOEi2PC=>
LN229 M1T2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPWbZRTOC13MDFOwG0> NFrVTFVKSzVyPUG2JO69VQ>? MoLkNlU4PTB{N{O=
TR-LN229 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDKNE02OCEQvF2= MnfMTWM2OD15NzFOwG0> MV:yOVc2ODJ5Mx?=
U87  NYDQcY1tSXCxcITvd4l{KEG|c3H5 NXrzRY1FOOLCk{KwNQKBkcL3TR?= M3:xPVI1KGh? NIW3bmdmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? MX6yOVY5OTZ4OB?=
U251MG MoLpRZBweHSxc3nzJGF{e2G7 MWexNFDDqM7:TR?= M3XVclQ5KGh? M1vF[nBDWw>? NX3p[plOcW6mdXPld{BieG:ydH;zbZM> MVOyOVY5ODR4NB?=
U87MG MXzBdI9xfG:|aYOgRZN{[Xl? MXSxNFDDqM7:TR?= NXTyV5ByPDhiaB?= M1z4ZnBDWw>? NHfEWItqdmS3Y3XzJIFxd3C2b4Ppdy=> NVO3NJp1OjV4OEC0OlQ>
U87 NFHHV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTwOVAuOzVyIN88US=> NHrZRm01QMLiaNMg NVuzRodFcW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? NVjTcpI5OjV3NUSyNlM>
U118  NE\5[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zVflUxNTN3MDFOwG0> MojNOFjDqGkEoB?= Mn7pbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NHjJWXczPTV3NEKyNy=>
U87 M13s[GZ2dmO2aX;uJGF{e2G7 NULTPZRzOjVyL{O1NEDPxE1? Ml3jOFjDqGkEoB?= NEnqT|JmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? NETRV2MzPTV3NEKyNy=>
U118  NVriTplCTnWwY4Tpc44hSXO|YYm= MUKyOVAwOzVyIN88US=> M2jYXFQ5yqCqwrC= MXPlcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> MmKyNlU2PTR{MkO=
U87 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTJNlUxNzN3MDFOwG0> MYq0POKhcMLi MX3pcoNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6gV{BidmRiR{KvUeKh[2:2cnXheIVlKHerdHigWG1Z M{GyelI2PTV2MkKz
A375 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37UT|Q5yqCqwrC= M3XoTWlEPTB;Mk[1JO69VQ>? NHv1RVgzPTV{NEW1Ni=>
A2058 NEG1copIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjWZoo1QMLiaNMg NYPUV3BLUUN3ME2xNkDPxE1? NVmyNGJYOjV3MkS1OVI>
M238 NXHTUHRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS0POKhcMLi M2PzdWlEPTB;NECg{txO NVvX[YlZOjV3MkS1OVI>
M249 NUjDVJBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm4[ZU1QMLiaNMg M13mb2lEPTB;MkW0JO69VQ>? M3G1[lI2PTJ2NUWy
M21 M2OzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3JT2s1QMLiaNMg M{fmS2lEPTB;MkKxJO69VQ>? MnzPNlU2OjR3NUK=
U251 NW\GWpYzS3m2b4TvfIl1gSCDc4PhfS=> NYLafJVvOjBizszNxsA> M1vLeFQ5yqCqwrC= M{DrXpJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= NX31fmNHOjV2M{SzPFE>
LN229 NGDZS2tEgXSxdH;4bZR6KEG|c3H5 NEXXeHozOCEQvF5CpC=> M4KyN|Q5yqCqwrC= NWjxXpM4emWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> M2qz[lI2PDN2M{ix
U373MG-LUC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIriNlM4OiCq MUfJR|UxRjZyMDFOwG0> NX\rW5huOjV2M{G5OVM>
U87  Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiyOU0zODBizszN MUW0POKhcMLi NUHRdJJycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M373XFI2PDByN{S1
U251 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFiwUZkzPS1{MECg{txO M3TCbVQ5yqCqwrC= M3nDTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYiyOVQxODd2NR?=
U251 M3q0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTzNVAxNTRyMDFOwG0> M2DEe|czNzl4IHi= NFXnR3F1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MWOyOVM4PTJ5MR?=
U373 M4PYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XjO|ExOC12MECg{txO NVvT[olsPzJxOU[gbC=> MoHseIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi Mo\nNlU{PzV{N{G=
U343 NUmwV4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\6eFExOC12MECg{txO NEe1VmY4Oi97NjDo NGDEXIJ1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MUeyOVM4PTJ5MR?=
U87MG-luc2 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;5eokyODBvNECwJO69VQ>? MWq3Nk86PiCq NXXNdJprfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NHzjXVUzPTN5NUK3NS=>
U87 M3v6dGZ2dmO2aX;uJGF{e2G7 M{ThVFIxOCEQvF2= MmT1OFghcA>? NXe1UocycW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= NGPrRYEzPTN|N{eyNS=>
U251 NVLEeHNqTnWwY4Tpc44hSXO|YYm= NIDXTlIzODBizszN NID0WGk1QCCq MXjpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v M125Z|I2OzN5N{Kx
A172 NGnlUGFHfW6ldHnvckBCe3OjeR?= NGDtOG8zODBizszN NV\uTmNYPDhiaB?= NFe4fW1qdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w NEfvR2QzPTN|N{eyNS=>
U251 MYfGeY5kfGmxbjDBd5NigQ>? NFq3d2UzODBizszN NIH6N4E1QCCq NHL4TWVqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ MWeyOVM{Pzd{MR?=
A172 MoLWSpVv[3Srb36gRZN{[Xl? NIPJO2szODBizszN MkO3OFghcA>? NXfTTJdncW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= Mnj0NlU{Ozd5MkG=
U87 M{HpXGZ2dmO2aX;uJGF{e2G7 MWmyNFAh|ryP NHHFdJEzPC95Mj:xNlAhcA>? M{HJe4lv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MlywNlU{Ozd5MkG=
U251 MWXGeY5kfGmxbjDBd5NigQ>? NFi4eGkzODBizszN NFX4cYUzPC95Mj:xNlAhcA>? NFfIW2VqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? MVKyOVM{Pzd{MR?=
A172 MY\GeY5kfGmxbjDBd5NigQ>? NIXDcG4zODBizszN NHPDVXgzPC95Mj:xNlAhcA>? M4TlWYlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? M1X2c|I2OzN5N{Kx
SNB19V MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW3JIQ> NIfBSZhFVVOR NX3UNYxYT0l3ME2zOU44yrFzMjFOwG0> M3K4clI2Ojd5NESx
SNB19M MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW3JIQ> NEPrS|JFVVOR M1fyNGdKPTB;NE[5MlnDuTh6IN88US=> NXX6UYN6OjV{N{e0OFE>
SNB19VR NWPHfWJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7yXHAzPyCm NV3STXU4TE2VTx?= NXrxdVJIT0l3ME2yPFAvOsLzMUig{txO M{nDclI2Ojd5NESx
U373V NGHDN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXeyT4V4PyCm NV7ZU3l1TE2VTx?= MkjyS2k2OD14OD6wxtE{OiEQvF2= NGjxco8zPTJ5N{S0NS=>
U373M M1XXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzJO{Bl MXrEUXNQ MXLHTVUxRTN4OD63xtE5PiEQvF2= NYLGVlNuOjV{N{e0OFE>
U373VR Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TUfVch\A>? NU\vWnJ1TE2VTx?= MYjHTVUxRTJ6OD64xtE{OyEQvF2= NF21R24zPTJ5N{S0NS=>
U87MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DJVFch\A>? NXHRTYFyTE2VTx?= MnPjS2k2OD1|OD6zxtEzOCEQvF2= NGjK[VUzPTJ5N{S0NS=>
HCT116 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW1O{Bl M2\Db2ROW09? NIDLWVRIUTVyPUW3PU46yrF|MjFOwG0> MXiyOVI4PzR2MR?=
DLD1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5XFch\A>? NHX0cY5FVVOR NV\SV5RsT0l3ME21NFEvPMLzOUOg{txO MmiyNlUzPzd2NEG=
MRC5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW3JIQ> Mn;0SG1UVw>? NE\LSWNIUTVyPUS0PU41yrF6IN88US=> MmHLNlUzPzd2NEG=
SNB19V  MoHmSpVv[3Srb36gRZN{[Xl? NWPJeVZJOTByIN88UeKhXE2c NFHRcZIxNTd{IHi= MVzpcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> NIDDZ4UzPTJ5N{S0NS=>
T98G  NFXRbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK1M|ExNzF3IN88US=> MmmzNlTDqGh? Ml[3bY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MUWyOVI3Ojl4MR?=
U251  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnkXZg5PS9zMD:xOUDPxE1? MWWyOOKhcA>? NXPWOnBycW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> Mkm1NlUzPjJ7NkG=
T98G  NUe3OmdwTnWwY4Tpc44hSXO|YYm= Mn60NVUh|ryP NH\WOHMzPMLiaB?= NYDEXnZ{cW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz MmjhNlUzPjJ7NkG=
U251  MXLGeY5kfGmxbjDBd5NigQ>? NXTWTZhQOTVizszN MUOyOOKhcA>? M333UIlv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= MXqyOVI3Ojl4MR?=
U-87 MG MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOy[Vk4OiCq NVSxUmRlUUN3ME2wMlk{KG2PwrC= M3XrSFI2OjR3M{Oy
U-118 MG NFPDcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7YZZM4OiCq Mnm1TWM2OD1zLkC1JI1OyqB? NGLTSI8zPTJ2NUOzNi=>
U87 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\zcIgzPCCq M3T0TmlEPTB;Mk[wMlM1KM7:TdMg NGfjSoYzPTF5M{KzNy=>
U87 GSLCs MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf4TWczPCCq M4PVbWlEPTB;N{[2MlEyKM7:TdMg M4\ubVI2OTd|MkOz
U87MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LYV|czKGh? M1zjNWlEPTB;MUWuOlI2KM7:TdMg MUCyOVA2ODlzNR?=
U251 NVrHTFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3yfYZ3OTByLUSwNEDPxE1? M{S1ZVQ5KGh? MX7EUXNQ NFW5W4ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYTz[XppOjR4MkO3N|Y>
U87 M2XZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXixNFAuPDByIN88US=> NX7O[XNuPDhiaB?= NHvrRpVFVVOR MoWwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2DTUlI1PjJ|N{O2
MDA-MB-231-br NVLtXoliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHiXYJ4OC1zMDFOwG0> NF[0U|k1QCCq NWfBXZhlTE2VTx?= MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUOwTIxCOjR4MkO3N|Y>
HCC-1937 M1;GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HuWVAuOzByIN88US=> MojjOFghcA>? MYfEUXNQ M4CyRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIT4RpEzPDZ{M{ezOi=>
MDA-MB-231 NXLTWW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTFRmhXOC12MDFOwG0> MmfHOFghcA>? NHnuepRFVVOR M4\CeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWKyOFYzOzd|Nh?=
MDA-MB-468 M{nUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3O|AuPTByIN88US=> M{DD[FQ5KGh? MnnoSG1UVw>? NGXKbnBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnLtNlQ3OjN5M{[=
T47D NHXMUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH63e5YxNTFyMDFOwG0> MUG0PEBp Mn\iSG1UVw>? MmP5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{HZTlI1PjJ|N{O2
MCF7 NX\jeJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVewMVExODBizszN NIrSTYo1QCCq Mn\TSG1UVw>? Mmr1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4[wUlI1PjJ|N{O2
Hs683 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGwMVExODBizszN MUm5OkBp M2HJdGlEPTB;MUK4Mlkh|ryP MXmyOFQ6PTlyNx?=
U87 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe0c3luOC1zMECwJO69VQ>? MWq5OkBp M{PIU2lEPTB;MUiuOFUh|ryP MlnGNlQ1QTV7MEe=
LNZ308 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHYNZgxNTFyMECg{txO M2LFOlk3KGh? NXLUSGdrUUN3ME2zNlYvPyEQvF2= MVmyOFQ6PTlyNx?=
U87 M3LuWmFxd3C2b4Ppd{BCe3OjeR?= NH\IeJkyODBizszN NFHNZoI1QCCq M4DnbmROW09? NXqwe2xkcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> M3r0XVI1PDhzNUi2
U251  M{fyc2Fxd3C2b4Ppd{BCe3OjeR?= NWW3XGFIOTByIN88US=> NGf1XWM1QCCq MWXEUXNQ MWLpcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 MX2yOFQ5OTV6Nh?=
U251 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0Z4ozPCCq MYXJR|UxRTh4LkK55qCKyrIkgJmxMlU5KM7:TR?= NF7WT2szPDN{Nkm1OC=>
U251 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FOFghcA>? MWLJR|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?= M{f6d|I1OzJ4OUW0
U251 NUXnPZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\xc|RlPzJiaB?= NHP6S5pKSzVyPUeyMlQz6oDLwsJihKkyNjR3IN88US=> NWGzdVE6OjR|Mk[5OVQ>
U251 M3\0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXBUmI5QTZiaB?= NE\vOZVKSzVyPU[5Mlgz6oDLwsJihKk{NjB2IN88US=> MlnQNlQ{OjZ7NUS=
T98G NIrPNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TMN|AuPzVyIN88US=> NUPkXHdIPzJxOU[gbC=> MoDGbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEHKSoozPDN{NEC4NC=>
U251-MG Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMVgxOCEQvF2= NUDmRmJ6PzJiaB?= M37SS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{Tle|I1ODl|NkOw
D54-MG MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWewMVgxOCEQvF2= M2X0RVczKGh? NX\ueYd4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mnu2NlQxQTN4M{C=
SHG-44 NFPlWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v0XVExNTJyMDFOwG0> MoPiPVYhcA>? M4noRmlEPTB;OT63N{DDuSB{LkGyJO69VQ>? MUSyOFA3PTV4OR?=
U373  M1q1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:xNE0zODBizszN NHzXWI46PiCq MXvJR|UxRTFyLkGzJOKyKDFwMEKg{txO NFHz[nozPDB4NUW2PS=>
HT-29  NEDCTXJHfW6ldHnvckBCe3OjeR?= M2XqOVUxOCEQvF2= MoSzNlQwPDhiaB?= MV\lcohidmOnczD0bIUhdGW4ZXzzJI9nKM7|LViyRXjDqA>? NVLNTnNjOjRyM{iwOlg>
PC-3  MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMVI2KM7:TR?= M3zleVQ5KGh? MlnnbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m MkfRNlM4PDZ7M{S=
PC-3  MYLBdI9xfG:|aYOgRZN{[Xl? NH7Bb5AzPSEQvF2= M2Gw[lQ5KGh? MlzqbY5lfWOnczDhdI9xfG:|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l Mn3rNlM4PDZ7M{S=
T98G MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyOVAuPDByIN88US=> MmPuNVQ1KGh? MmnxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1[wZVI{PzF3NEm5
U87-MG NU\Sd4d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2NVAxKML3TR?= M{TYZlczKGh? NWrsRVhHcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MkDxNlM3QTZ5OEi=
U251-MG NUPGWngyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fSelExOCEEtV2= MlfyO|IhcA>? NHXkU3dqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWg[Y5p[W6lZXSgZpkhT1SE NXLWfVFDOjN4OU[3PFg>
LNT-229 NWXaPZluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HhUFMuOTByIN88US=> MojZNlQhcA>? M2fTfolvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVeyN|Y3PzZ|Mh?=
T98G MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnTNVAuPzByIN88US=> MVuyOEBp MVvpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NELZNoEzOzZ4N{[zNi=>
U87  MYLGeY5kfGmxbjDBd5NigQ>? MoXqNVAxKML3TR?= NEHyc3g{KGh? NIC5dY1mdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>? M{G0ZlI{PjZ5NE[5
HCT116 MXzGeY5kfGmxbjDBd5NigQ>? NHzoPIIyODBiwsXN MYOzJIg> NEXsXoJqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= MUeyN|Y3PzR4OR?=
HCT3-6 NF3BSJVHfW6ldHnvckBCe3OjeR?= MVGxNFAhyrWP M{XKZ|MhcA>? NY\FdXNNcW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= NH;rUIMzOzZ4N{S2PS=>
U-87  NYrJNGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWwd3dNOC12MDFOwG0> NUDxOIdVOTJiZB?= MofPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVPPZXR1OjN4NEW3Nlk>
U-87  NF;5fo5CeG:ydH;zbZMhSXO|YYm= MV6wMVQxKM7:TR?= NXnkbYJ[Oy94IHS= NVXqUo5jcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MYSyN|Y1PTd{OR?=
U-87  NWLtToR3TnWwY4Tpc44hSXO|YYm= NIjkbJIxNTRyIN88US=> M2rVeVMwPiCm MofQbY5lfWOnczDheZRweGijZ4mgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MWWyN|Y1PTd{OR?=
GB-SCC010 NF7GepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnm[Gk1KGR? NHXVWIFKSzVyPUKyOkDPxE1? NGD6W4kzOzZzMke1OS=>
GB-SCC026 NYHCfXdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;OOEBl MYTJR|UxRTV|LkGg{txO MVOyN|YyOjd3NR?=
GB-SCC028 NIPjV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV20JIQ> NYXV[pI4UUN3ME2xOlch|ryP Mn6xNlM3OTJ5NUW=
U87 NXvGXWprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITx[Ic1KGR? MXLJR|UxRTR3LkKg{txO NV\MbW97OjN4MUK3OVU>
U87 stem cell MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrKOEBl NX7mXpFtUUN3ME22Ok44KM7:TR?= M{LLdFI{PjF{N{W1

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03688178 Not yet recruiting Glioblastoma Gary Archer Ph.D.|Duke University January 2019 Phase 2
NCT03732482 Not yet recruiting Non Small Cell Lung Cancer Metastatic Taizhou Hospital January 1 2019 Phase 2|Phase 3
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03705351 Not yet recruiting Glioblastoma|Cancer of Brain|Glioblastoma Multiforme|Brain Tumor Providence Health & Services|Providence Health & Services Brain & Spine Institute|University of California San Francisco|NovoCure Ltd. December 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID